Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A injection in surgical repair of large incisional hernia
2023-504554-35-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in incisional hernia comparing Xeomin arm with Placebo arm (2 arms). Primary endpoint: Primary: Clavien-Dindo grade II or higher postoperative complication within 90 days. Planned start Apr 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
incisional hernia
Beyond the preview
Go deeper on 2023-504554-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504554-35-00.